Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Ther Pat. 2013 May;23(5):669-75. doi: 10.1517/13543776.2013.779254. Epub 2013 Mar 19.

New selective inhibitors of MMP-13 for inflammatory diseases: a patent evaluation (W02012151158).

Author information

  • 1Nanjing University of Chinese Medicine, Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing, Jiangsu, P. R. China.


A series of compounds incorporating an aromatic scaffold based on isoxazolines were prepared in the patent application (WO2012151158). The new compounds from the patent are defined to be biologically active metabolites, prodrugs, isomers, stereoisomers, solvates, hydrates and pharmaceutically acceptable salts, they are claimed to be useful for treating immunological conditions because of their inhibitory activities on matrix metalloproteinase (MMP-13), although no specific MMP-13 inhibition data or other rationale to explain their biological effects is provided. The compounds have a broad potential utility with osteoarthritis, rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, degenerative joint disease or systemic lupus erythematosus among the likely preferred indications.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center